COVID-19: Pharmacology and kinetics of viral clearance

Pharmacol Res. 2020 Nov:161:105114. doi: 10.1016/j.phrs.2020.105114. Epub 2020 Aug 3.

Abstract

Coronavirus Disease 2019 (COVID-19) is a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical spectrum of COVID-19 is broad and varies from mild to severe forms complicated by acute respiratory distress and death. This heterogeneity might reflect the ability of the host immune system to interact with SARS-CoV2 or the characteristics of the virus itself in terms of loads or persistence. Information on this issue might derive from interventional studies. However, results from high-quality trials are scarce. Here we evaluate the level of evidence of available published interventional studies, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes. Moreover, we present data on a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients.

Keywords: COVID-19; Pharmacology; SARS-CoV-2; Viral clearance kinetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • COVID-19 / virology*
  • COVID-19 Drug Treatment*
  • Humans
  • SARS-CoV-2*
  • Viral Load

Substances

  • Antiviral Agents